FOR IMMEDIATE RELEASE
Solid Technologies and XtalPi Enter into Partnership Agreement on Solid State and Computational Drug Development Services
Barcelona, Spain, and Cambridge, MA – August 6, 2024 – Solid Technologies S.L. (Solitek), a leading provider of solid-state development services, has entered into a strategic agreement with XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials. This collaboration combines Solitek’s solid-state expertise with XtalPi’s advanced computational tools, offering comprehensive solutions to pharmaceutical clients across Europe.
Effective August 6, 2024, the partnership allows Solitek to integrate XtalPi’s proprietary AI-powered crystal structure prediction (CSP) platform, a technology that can drastically de-risk conventional polymorph screening approaches, into its offerings. In return, XtalPi’s European clients will gain access to Solitek’s solid-state wet lab services as part of a complementary solid-state research service portfolio. Both companies will promote and offer each other’s services, enhancing their regional presence and providing clients with a unified solution in the European market.
“This partnership is a significant step for Solitek as we expand into new markets with XtalPi’s AI-driven platforms,” said Victor Diaz, co-founder and Operations Director of Solitek. “Together, we’ll accelerate drug development for our clients with cutting-edge solutions.”
Dalong Hu, Head of the Solid-State Business Unit at XtalPi, added, “Our AI-driven CSP platform, coupled with experimental screening, sets a new standard for thoroughness, speed, and quality in solid-state research. Partnering with Solitek allows us to broaden our impact in Europe, propelling the development of innovative medicines at a greater scale.”
About Solitek:
Solid Technologies S.L. (Solitek) offers state-of-the-art solid state development services to the pharmaceutical, agrochemical, and fine chemical industries. Solitek was launched in 2021 and is located in the Parc Cientific of Barcelona, Spain. The founders have long careers in the pharmaceutical industry, including a combined experience of over 40 years in the world of solid state research and crystallization development, having led some of the largest teams in Europe dedicated to the provision of solid state services. Solitek offers stage-appropriate development for each program, focusing on problem solving to help clients reduce the risk of failure during the later development stages.
About XtalPi:
XtalPi (“QuantumPharm Inc.”, stock code: 2228.HK) is a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform company. Established in 2015 by three postdoctoral physicists at Massachusetts Institute of Technology (MIT), the company is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally.
Contact Information:
Solitek: Victor Diaz, Operations Director
Email: victor.diaz@solitekpharma.com Phone: +34 644 429 321
